The BMS-Pfizer Alliance is committed to supporting healthcare professionals and the NHS to drive improvements in patient care. The BMS-Pfizer Alliance supports the submission of grant requests from healthcare organisations to provide funding for the independent medical and/ or scientific initiatives of that healthcare organisation, that are aligned to the BMS-Pfizer Alliance’s medical and/or scientific strategies. One of the ways in which we do this, is by providing Quality Improvement Grants.
QUALITY IMPROVEMENT GRANTS
Quality Improvement Grants are intended to either enhance patient care or benefit the NHS and maintain patient care. This type of medical grant is to provide funding for independent projects for systematic and continuous actions that lead to measurable improvement in health care services and the health status of individuals and targeted patient groups, and do not relate to a BMS-Pfizer asset. Quality improvement considers aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators, and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice.
Grants are intended for healthcare organisations that are comprised of health professionals and provide healthcare. They cannot be linked to the prescribing or use of a specific medicine. As a result, the BMS-Pfizer Alliance’s involvement is strictly limited to the provision of the Quality Improvement Grant and we do not receive any direct benefit in return. Quality Improvement Grants do not constitute an inducement to prescribe, supply, administer, recommend, buy or sell any medicine.
Information about grants is contained within the ABPI Code of Practice and can be explored in interactive form on the Prescription Medicines Code of Practice Authority (PMCPA) website.
PP-INT-GBR-0334 | July 2021